| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence
|
Sandner, Peter
|
|
2017
|
122 |
S1 |
p. S1-S9
9 p.
|
artikel
|
| 2 |
Idiopathic interstitial pneumonia-associated pulmonary hypertension: A target for therapy?
|
Nathan, Steven D.
|
|
2017
|
122 |
S1 |
p. S10-S13
4 p.
|
artikel
|
| 3 |
Rationale and study design of MOTION: A phase 4, prospective, single-arm, open-label study to measure outcomes in patients with pulmonary arterial hypertension not on active treatment
|
Mathai, Stephen C.
|
|
2017
|
122 |
S1 |
p. S23-S27
5 p.
|
artikel
|
| 4 |
Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors
|
Hoeper, Marius M.
|
|
2017
|
122 |
S1 |
p. S18-S22
5 p.
|
artikel
|
| 5 |
RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis
|
Distler, Oliver
|
|
2017
|
122 |
S1 |
p. S14-S17
4 p.
|
artikel
|
| 6 |
sGC stimulators: Evidence for riociguat beyond groups 1 and 4 pulmonary hypertension
|
Benza, Raymond
|
|
2017
|
122 |
S1 |
p. S28-S34
7 p.
|
artikel
|
Tijdschrift beschrijving